The current hormonal treatment strategies for advanced prostate cancer are based on two principal therapeutic approaches: inhibition of conversion of extragonadal precursor steroids to testosterone and 5α-dihydrotestosterone (DHT) with abiraterone and direct blockade of the AR to prevent binding to its ligands, testosterone, and DHT with next-generation AR antagonists, such as apalutamide, darolutamide, or enzalutamide [22]. This evidence concerns the gene AR and prostate carcinoma.